In a 48‑week multicenter phase 2 trial, weekly amylin receptor agonist eloralintide produced dose‑dependent mean weight loss of 9.4%–20.9% versus 0.4% for placebo, with improved waist circumference and cardiometabolic markers; tolerability improved with stepwise dose escalation.